AC Immune SA (ACIU)
| Market Cap | 263.48M +26.5% |
| Revenue (ttm) | 21.67M -39.5% |
| Net Income | -53.41M |
| EPS | -0.53 |
| Shares Out | 99.43M |
| PE Ratio | n/a |
| Forward PE | 43.26 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105,642 |
| Open | 2.730 |
| Previous Close | 2.710 |
| Day's Range | 2.650 - 2.770 |
| 52-Week Range | 2.030 - 4.000 |
| Beta | 1.57 |
| Analysts | Strong Buy |
| Price Target | 8.58 (+223.77%) |
| Earnings Date | Aug 5, 2026 |
About ACIU
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow A... [Read more]
Financial Performance
In 2025, AC Immune's revenue was 3.57 million, a decrease of -86.92% compared to the previous year's 27.31 million. Losses were -70.45 million, 38.4% more than in 2024.
Financial numbers in CHF Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ACIU stock is "Strong Buy." The 12-month stock price target is $8.58, which is an increase of 223.77% from the latest price.
News
AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating ACI-19764, an NLRP3 inhibitor targeting inflammation.
AC Immune receives fast track designation, clearance for ACI-7104 IND
AC Immune (ACIU) announced that it has received fast track designation and clearance of its investigational new drug, or IND, application from the FDA for its wholly owned anti-alpha-synuclein active…
AC Immune First Half 2026 Financial and Corporate Update
AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs approach near-term clinical catalysts as partnered programs generate milestone payments Key advances...
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026
AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lausanne, Switzerland, July 7, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical ...
AC Immune announces interim data from first three cohorts of ABATE trial
AC Immune (ACIU) announced interim data from the first three cohorts of 74 patients with prodromal Alzheimer’s disease in the Phase 1b/2 ABATE trial following 12 months of treatment with…
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease
AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer's Disease ACI-24 anti-Abeta active immunotherapy generally safe and well tolerated in first three A...
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's Disease Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 Planned extension of P...
AC Immune Slides: Investor presentation
AC Immune has posted slides in relation to its latest quarterly earnings report, which was published on June 5, 2026.
AC Immune presents new Phase 1 data on uptake of ACI-19626
AC Immune (ACIU) SA announced the presentation of new preliminary data from a Phase 1 trial of its first-in-class TDP-43 positron emission tomography tracer ACI-19626 showing increased uptake in the…
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALS Presentation at 2026 TDP43 Summit shows ACI-19626 detects TDP-43 pathology in patients ...
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer's Policy, Research and Care
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appoi...
AC Immune reports Q1 EPS (15c), consensus (14c)
Reports Q1 revenue $1.12M, consensus $263,230. Andrea Pfeifer, CEO of AC Immune (ACIU) SA, commented: “The progress in our collaborations with Takeda and Eli Lilly reflect great confidence in our…
AC Immune First Quarter 2026 Financial and Corporate Updates
AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteer...
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 ...
AC Immune Earnings release: Q1 2026
AC Immune released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
AC Immune Slides: Investor presentation
AC Immune has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Leerink calls AC Immune- Eli Lilly Tau amendment ‘great news’
Leerink analyst Marc Goodman says AC Immune’s (ACIU) amendment of the collaboration agreement with Eli Lilly (LLY) for the Morphomer Tau program is “great news” and underscores the continued interest…
AC Immune announces amendment to Eli Lilly license pact, to receive CHF 10M
AC Immune (ACIU) announced an agreement with Eli Lilly (LLY) to amend their 2018 license and collaboration agreement to research and develop Tau aggregation inhibitor small molecules for the potential...
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly
AC Immune Announces Amendment to Morphomer ® Tau License and Collaboration Agreement with Lilly Amended agreement reflects growing excitement in the field for targeting intracellular Tau and significa...
AC Immune’s PET tracer shows efficacy detecting brain pathologies
AC Immune (ACIU) announced the presentation of Phase 1 data including the first in vivo images of TDP-43 pathology in the human brain, detected using its positron emission tomography –…
AC Immune reports FY25 EPS (CHF 0.70) vs (CHF 0.51) last year
Reports FY25 revenue CHF 3.753M vs CHF 27.309M last year. Dr. Andrea Pfeifer, CEO of AC Immune (ACIU) SA, commented: “We made significant progress towards delivering precision prevention of neurodegen...
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update
AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's ...
AC Immune Earnings release: Q4 2025
AC Immune released its Q4 2025 earnings on March 13, 2026, summarizing the period's financial results.
AC Immune Annual report: Q4 2025
AC Immune has published its Q4 2025 annual report on March 13, 2026.